Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869504 | 0.84 | NR1I2 (0.34) | MAPTLMNASLC2A1 | |
| SCHEMBL21346764 | 0.84 | NR1I2 (0.34) | MAPTLMNASLC2A1 | |
| SCHEMBL19231990 | 0.82 | NPC1 (0.39) | GPR84OPRM1SPHK1MAPTLMNA | |
| SCHEMBL19853062 | 0.82 | DNM1 (0.34) | MAPTLMNASLC2A1 | |
| SCHEMBL22930734 | 0.80 | GPR84 (0.35) | GPR84OPRM1SLC2A1 | |
| SCHEMBL26078440 | 0.79 | GPR84 (0.40) | GPR84OPRM1SPHK1LMNA | |
| SCHEMBL20374383 | 0.79 | GPR84 (0.40) | GPR84OPRM1SPHK1LMNA | |
| SCHEMBL18879333 | 0.78 | APLNR (0.40) | GPR84 | |
| SCHEMBL27814538 | 0.77 | OPRM1 (0.38) | GPR84OPRM1LMNA | |
| SCHEMBL19464656 | 0.77 | GPR84 (0.37) | GPR84SPHK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | GPR84 2521/4885OPRM1 2345/4885SPHK1 981/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | GPR84 2521/4885OPRM1 2345/4885SPHK1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.